Codeine is a naturally occurring opioid found in the opium poppy that is widely used in cough suppressants and combination analgesics. In many countries, codeine-containing products are available over the counter or with minimal prescription oversight, which creates a false impression of safety. Codeine is a prodrug that the liver converts to morphine via the CYP2D6 enzyme, and it produces the same mu-opioid receptor activation, tolerance, physical dependence, and addiction potential as other opioids. Over-the-counter availability does not equal low risk, and codeine dependence is a clinically significant condition that requires proper medical management.
Clinically reviewed by Dr. Ponlawat Pitsuwan, Physician, Phuket Island Rehab
“Codeine dependence is one of the most underdiagnosed substance use disorders we encounter,” says Dr. Ponlawat Pitsuwan. “At Phuket Island Rehab, we regularly see patients who have been purchasing codeine products from pharmacies for years, sometimes consuming dozens of tablets per day. Many do not consider themselves to have a drug problem because the substance was purchased legally over a pharmacy counter. The pharmacological reality is that their brains have undergone the same opioid-driven neuroadaptation as someone dependent on prescription oxycodone.”
How Codeine Becomes Morphine in the Body
Codeine itself has relatively low affinity for mu-opioid receptors. Its analgesic and euphoric effects depend almost entirely on its conversion to morphine by the hepatic enzyme CYP2D6. Approximately 5 to 10% of an oral codeine dose is O-demethylated to morphine, and it is this morphine that binds mu-opioid receptors in the brainstem, thalamus, and limbic system to produce analgesia, cough suppression, and the rewarding effects that drive dependence.
The CYP2D6 enzyme shows significant genetic polymorphism across populations. Poor metabolisers (approximately 5 to 10% of Caucasians, 1 to 2% of East Asians) produce very little morphine from codeine and experience minimal analgesic effect. Ultra-rapid metabolisers (1 to 7% of the population, with higher prevalence in North African, Ethiopian, and Middle Eastern populations) convert codeine to morphine much faster and in greater quantities, placing them at elevated risk of toxicity, respiratory depression, and rapid dependence development even at standard doses. The FDA issued a boxed warning in 2017 restricting codeine use in children under 12 after several paediatric deaths linked to ultra-rapid CYP2D6 metabolism.
Why Over-the-Counter Access Fuels Dependence
In many countries, including Australia, the United Kingdom (until 2018 reclassification of some products), parts of Southeast Asia, and much of Africa, codeine-containing analgesics and cough preparations are available without prescription or through a brief pharmacist consultation. This accessibility creates several pathways to dependence. The initial use is often for a legitimate symptom: a persistent cough, a headache, menstrual pain, or dental pain. Because codeine provides effective short-term relief and produces a mild sense of well-being, the user returns to it whenever symptoms recur.
Over time, tolerance develops. The original two-tablet dose no longer provides the same relief, so the user increases to three, then four, then begins taking multiple doses throughout the day. Physical dependence establishes itself within weeks of daily use, and the user now experiences withdrawal symptoms (anxiety, restlessness, muscle aches, insomnia) whenever they try to stop. At this point, use continues not for pain relief but to avoid withdrawal, and the user may visit multiple pharmacies to obtain sufficient supply, a behaviour known as “pharmacy shopping.”
The Ibuprofen-Codeine and Paracetamol-Codeine Danger
Most over-the-counter codeine products are combination formulations containing either ibuprofen (as in Nurofen Plus) or paracetamol (acetaminophen, as in Panadeine or Tylenol with Codeine). These combinations create a particularly insidious harm pattern: as the user escalates their codeine intake to manage tolerance, they simultaneously consume dangerously high doses of the co-formulated analgesic.
Warning: Chronic high-dose consumption of paracetamol-codeine combinations can cause severe hepatotoxicity (liver damage). Paracetamol doses exceeding 4,000 mg per day are associated with acute liver failure. Chronic ibuprofen-codeine misuse causes gastrointestinal ulceration, perforation, renal impairment, and hypokalaemia (dangerously low potassium). Deaths from these co-formulated analgesic harms are well documented in medical literature.
A person taking 20 to 30 tablets of a paracetamol-codeine combination daily (a pattern seen in established codeine dependence) may be consuming 10,000 to 15,000 mg of paracetamol, more than three times the maximum safe daily dose. The liver damage this causes is often silent until advanced, presenting as elevated liver enzymes, jaundice, or acute liver failure. Similarly, chronic high-dose ibuprofen use causes gastric and duodenal ulceration, gastrointestinal bleeding, and progressive renal impairment that may not produce symptoms until significant organ damage has occurred.
Codeine-Containing Products and Risk Levels
| Product Type | Codeine Per Dose | Co-formulated Drug | Primary Escalation Risk |
|---|---|---|---|
| Codeine phosphate tablets (prescription) | 15 to 60 mg | None | Opioid dependence, respiratory depression |
| Paracetamol-codeine (e.g., Panadeine, Tylenol #3) | 8 to 30 mg | Paracetamol 500 mg | Hepatotoxicity (liver damage) from paracetamol accumulation |
| Ibuprofen-codeine (e.g., Nurofen Plus) | 12.8 mg | Ibuprofen 200 mg | GI ulceration, renal impairment, hypokalaemia |
| Codeine linctus (cough syrup) | 15 mg per 5 mL | None or guaifenesin | Opioid dependence, escalating volume consumption |
| Promethazine-codeine syrup (“lean,” “purple drank”) | 10 mg per 5 mL | Promethazine 6.25 mg | Combined CNS depression, respiratory depression |
“Lean” and Codeine Cough Syrup Misuse
Promethazine-codeine cough syrup, known colloquially as “lean,” “purple drank,” or “sizzurp,” is typically mixed with a soft drink and hard candy. This combination has been popularised in hip-hop culture and is particularly prevalent among younger users. The promethazine component is a first-generation antihistamine with sedative properties that enhances the CNS depressant effects of codeine. The combination produces a euphoric, sedated state that users describe as relaxing.
The danger of lean is the combined respiratory depression from codeine (mu-opioid agonist effect) and promethazine (H1 receptor antagonism plus anticholinergic effects). Several high-profile deaths have been attributed to this combination. The sweet taste of the mixed drink also encourages overconsumption because the user does not perceive a drug-like taste that might otherwise prompt caution. Chronic use produces opioid dependence, antihistamine tolerance, and the same withdrawal syndrome as other forms of codeine dependence.
Codeine Withdrawal
Codeine withdrawal follows the standard opioid withdrawal pattern because the active compound at the receptor level is morphine. Symptoms typically begin 12 to 24 hours after the last dose and include anxiety, irritability, muscle aches, lacrimation, rhinorrhoea, sweating, yawning, insomnia, nausea, vomiting, diarrhoea, abdominal cramping, dilated pupils, and piloerection (goosebumps). Peak severity occurs at 48 to 72 hours, and acute symptoms generally resolve within 5 to 7 days.
Post-acute withdrawal symptoms, including insomnia, dysphoria, reduced energy, and intermittent cravings, may persist for weeks to months. For patients who have been consuming high-dose combination products, the withdrawal period may also involve recovery from the organ damage caused by the co-formulated analgesic, requiring monitoring of liver function (for paracetamol combinations) or renal function and electrolytes (for ibuprofen combinations).
Clinical insight: At Phuket Island Rehab, codeine-dependent patients undergo baseline blood work including liver function tests (ALT, AST, bilirubin), renal function (creatinine, eGFR), full blood count, and electrolytes before detoxification begins. This screening frequently reveals subclinical organ damage that the patient was unaware of and that informs the medical management of their withdrawal and ongoing care.
When Substance Use Has Become More Than Occasional
The progression from occasional codeine use to dependence is often gradual enough that the person does not recognise the transition. Key indicators include needing codeine to get through a normal day, feeling unwell or anxious when a dose is delayed, purchasing codeine products from multiple sources, taking more tablets than the packet recommends, continuing to use codeine after the original pain or cough has resolved, and feeling defensive or secretive about consumption. If these patterns are present, they meet multiple DSM-5 criteria for opioid use disorder.
Codeine dependence responds to the same evidence-based treatments used for other opioid use disorders. Medical detoxification, potentially including buprenorphine-assisted tapering for severe dependence, addresses the physical component. Residential treatment programmes like Phuket Island Rehab provide the therapeutic environment to address the psychological drivers of use, develop alternative coping strategies, and establish a sustained recovery framework.
Summary
Codeine’s widespread over-the-counter availability in many countries creates a false equivalence between accessibility and safety. Codeine is converted to morphine in the liver, activates the same mu-opioid receptors as all other opioids, and produces genuine tolerance, physical dependence, and addiction through identical neuroadaptive mechanisms. The additional danger of combination products means that codeine-dependent individuals are often simultaneously causing serious organ damage from paracetamol or ibuprofen without realising it.
“When a patient tells me they are only taking something from the pharmacy, not anything illegal, I know we need to have a careful conversation about what codeine actually is,” says Dr. Ponlawat Pitsuwan. “The legal status of a substance has no bearing on its pharmacology. Codeine becomes morphine in the body, and the brain does not distinguish between morphine from a pharmacy product and morphine from any other source. Recognising this is the first step toward appropriate treatment.”
Frequently Asked Questions
How quickly can you become dependent on codeine?
Physical dependence on codeine can develop within two to four weeks of daily use, though the timeline varies based on dose, individual metabolism (particularly CYP2D6 status), and prior opioid exposure. Some individuals report withdrawal symptoms after as little as two weeks of regular use. Psychological dependence, characterised by craving and habitual use, may develop alongside or even before physical dependence, particularly if the codeine is being used to manage emotional distress rather than purely physical pain.
Is codeine stronger than paracetamol alone?
Codeine provides a different type of analgesia. Paracetamol works primarily through central inhibition of cyclooxygenase enzymes and activation of descending serotonergic pathways. Codeine, via its conversion to morphine, acts on mu-opioid receptors in the spinal cord and brain. The combination provides modestly better pain relief than paracetamol alone for some types of pain, but systematic reviews (including Cochrane analyses) have found that the additional benefit of low-dose codeine is often clinically marginal, while the risks of dependence are real. For many pain conditions, paracetamol or ibuprofen alone, or their combination without codeine, provides adequate relief without opioid risk.
Can codeine cause liver damage?
Codeine itself does not directly cause liver damage. The hepatotoxicity risk comes from the paracetamol that is co-formulated in many codeine products. When a person escalates their codeine intake due to tolerance, they simultaneously increase their paracetamol consumption, often far beyond safe limits. Paracetamol is metabolised in the liver, and at high doses, a toxic metabolite (NAPQI) accumulates faster than the liver can neutralise it with glutathione, causing hepatocellular necrosis. This can progress to acute liver failure, which is life-threatening.
Is codeine withdrawal dangerous?
Codeine withdrawal is generally not life-threatening in otherwise healthy adults, though it is extremely uncomfortable. The main medical risks are dehydration from vomiting and diarrhoea, electrolyte imbalances, and the risk of relapse followed by overdose (because tolerance decreases during abstinence). For patients who have been consuming high-dose combination products, the concurrent organ damage from paracetamol or ibuprofen may require separate medical management. Medical supervision during withdrawal ensures symptom management and monitoring of any co-existing organ damage.
Why was codeine rescheduled in Australia?
In February 2018, Australia upscheduled all codeine-containing products from over-the-counter (Schedule 2 and 3) to prescription-only (Schedule 4). The Therapeutic Goods Administration made this decision based on evidence of widespread codeine dependence, deaths from co-formulated analgesic harm (particularly paracetamol hepatotoxicity and ibuprofen nephrotoxicity), and data showing that codeine added only marginal analgesic benefit over non-opioid alternatives. Post-rescheduling studies showed reductions in codeine-related harms and emergency presentations.
Can you use MAT medications for codeine addiction?
Yes. Buprenorphine (Suboxone, Sublocade) and naltrexone (Vivitrol) are appropriate for codeine use disorder, just as they are for other opioid use disorders. For severe codeine dependence with high-dose use, buprenorphine-assisted tapering can significantly ease withdrawal and reduce relapse risk. For patients who complete detoxification and seek relapse prevention, monthly naltrexone injections block the opioid effects of codeine and reduce the reinforcement of any use. The choice of MAT medication depends on the severity of dependence, co-occurring conditions, and the patient’s treatment goals.
Sources
Therapeutic Goods Administration (TGA). “Codeine information hub: changes to patient access for medicines containing codeine.” tga.gov.au
US Food and Drug Administration. “FDA Drug Safety Communication: FDA restricts use of prescription codeine pain and cough medicines and tramadol pain medicines in children.” fda.gov
National Institute on Drug Abuse (NIDA). “Prescription Opioids DrugFacts.” National Institutes of Health. drugabuse.gov
Codeine · O-demethylation · Morphine · CYP2D6 · Mu-opioid receptor · Paracetamol (acetaminophen) · Hepatotoxicity · NAPQI · Ibuprofen · Nephrotoxicity · Hypokalaemia · Promethazine · Lean · Ultra-rapid metaboliser · Buprenorphine · Naltrexone · Opioid use disorder · DSM-5 · Phuket Island Rehab